nidНефрология и диализNephrology and Dialysis1680-44222618-9801Российское диализное обществоnid-3728Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESПрименение мофетил-микофенолата у реципиентов аллогенных почек в различные сроки после трансплантацииMofetil-mykophenolate administration in recipients of allogenic kidney in different post-transplantation periodsКаабакМ. М.KaabakM. M.gantier@mail.med.ruГоряйновВ. А.GoriainovV. A.noemail@neicon.ruМолчановаЕ. А.MolchanovaE. A.noemail@neicon.ruОтдел трансплантации органов, лаборатория клинической иммунологии Российского научного центра хирургии РАМНRussian Federation200128062025315256Copyright © Каабак М.М., Горяйнов В.А., Молчанова Е.А., 20252025Каабак М.М., Горяйнов В.А., Молчанова Е.А.Kaabak M.M., Goriainov V.A., Molchanova E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephro.ru/jour/article/view/3728

ММФ был использован у 15 реципиентов аллогенных почек в сроки от 1 до 48 месяцев после трансплантации. Показаниями к назначению ММФ были: острое отторжение (7 больных), хроническое отторжение (6 больных), циклоспориновая нефропатия (1 больной), нефропатия неясной этиологии. Положительный результат был достигнут у 12 больных, у 3 - препарат был неэффективен. Наши наблюдения привели к заключению, что ММФ эффективен как при остром, так и при хроническом отторжении. Нами отмечено, что ММФ более эффективен в отдаленные сроки после операции. Осложнения ММФ-терапии мы наблюдали только у 2 больных (диарея), которые прошли после перевода больных на прием препарата после еды.

MMF was administrated in 15 recipients of allogenic kidneys at various periods after the operation (1 to 48 months). Indications to MMF were: acute rejection (7 patients), chronic rejection (6 patients), CyA-nephropathy (1 patient) and unclear nephropathy (1 patient). MMF was effective in 12 patients. Our experience with MMF allows us to conclude, that: 1) MMF is effective both in acute and chronic rejection, 2) MMF is much more effective at late period after transplantation, than at the early one. Only 2 patients had a diarrhea which was cut off after these patients were conversed on after meal taking MMF.

трансплантацияпочкамофетил-микофенолатотторжениеReferencesEuropean Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet, 1995; 345; 1321-1325.European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet, 1995; 345; 1321-1325.Sollinger H.W. for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allografts recipients. Transplantation, 1995; 60; 225-232.Sollinger H.W. for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allografts recipients. Transplantation, 1995; 60; 225-232.Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomisied, clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation.Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomisied, clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation.Mathew T.H. for The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, long-term randomisied multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Results at 3 years. Transplantation, 1998; 65: 1450-1454.Mathew T.H. for The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, long-term randomisied multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Results at 3 years. Transplantation, 1998; 65: 1450-1454.Pretagostini R., Rossi M., Berloco P. et al. Mofetil mycophenolate in renal transplantation. Abtsr. of Intern. Congr. of the Transplant. Soc., Rome, 2000, aug. 27 - sept. 1, 5.Pretagostini R., Rossi M., Berloco P. et al. Mofetil mycophenolate in renal transplantation. Abtsr. of Intern. Congr. of the Transplant. Soc., Rome, 2000, aug. 27 - sept. 1, 5.Weir V.R., Anderson L., Fink J.C. et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation, 1997; 64: 1706-1710.Weir V.R., Anderson L., Fink J.C. et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation, 1997; 64: 1706-1710.Hueso M., Bover J., Seron D. et al. Low-dose cyclosporine and mycophenolate mofetil in renal allografts recipients with suboptimal renal function. Transplantation, 1998; 65.Hueso M., Bover J., Seron D. et al. Low-dose cyclosporine and mycophenolate mofetil in renal allografts recipients with suboptimal renal function. Transplantation, 1998; 65.Sheketa M., McGrath J. The safety and efficacy of complete cyclosporine withdrawal and substitution with mycophenolate mofetil in patients with chronic allograft nephropathy. Abstr. of Intern. Congr. of the Transplant. Soc., Rome, 2000, aug. 27 - sept. 1.Sheketa M., McGrath J. The safety and efficacy of complete cyclosporine withdrawal and substitution with mycophenolate mofetil in patients with chronic allograft nephropathy. Abstr. of Intern. Congr. of the Transplant. Soc., Rome, 2000, aug. 27 - sept. 1.Oyo A.O., Meier-Kriesche H.-U. et al. Mycophenolate mofetil decreases the risk for chronic renal allograft failure. Abstr. of Intern. Congr. of the Transplant. Soc., Rome, 2000, aug. 27 - sept. 1.Oyo A.O., Meier-Kriesche H.-U. et al. Mycophenolate mofetil decreases the risk for chronic renal allograft failure. Abstr. of Intern. Congr. of the Transplant. Soc., Rome, 2000, aug. 27 - sept. 1.Land W., Schneerberger H., Stumpfig L. et al. Long-term application of mycophenolate mofetil monotherapy: safe and efficacious maintenance immunosuppression in kidney transplanted patients. Abstr. of Intern. Congr. of the Transplant. Soc., Rome, 2000, aug. 27 - sept. 1.Land W., Schneerberger H., Stumpfig L. et al. Long-term application of mycophenolate mofetil monotherapy: safe and efficacious maintenance immunosuppression in kidney transplanted patients. Abstr. of Intern. Congr. of the Transplant. Soc., Rome, 2000, aug. 27 - sept. 1.Grinyo J.M. Place of mycophenolate mofetil. Abstr. of Intern. Congr. of the Transplant. Soc., Rome, 2000, aug. 27 - sept. 1.Grinyo J.M. Place of mycophenolate mofetil. Abstr. of Intern. Congr. of the Transplant. Soc., Rome, 2000, aug. 27 - sept. 1.McGrath J., Shehata M. Complete withdrawal of cyclosporin in chronic allograft nephropathy: a randomised prospective trial of conversion to mycophenolate mofetil or tacrolimus. Abstr. of Intern. Congr. of the Transplant. Soc.,Rome, 2000, aug. 27 - sept. 1.McGrath J., Shehata M. Complete withdrawal of cyclosporin in chronic allograft nephropathy: a randomised prospective trial of conversion to mycophenolate mofetil or tacrolimus. Abstr. of Intern. Congr. of the Transplant. Soc.,Rome, 2000, aug. 27 - sept. 1.Hardwick L., Savatta S., Book B. et al. Effect of mycophenolate mofetil (MMF) on anti-CMV serologic response after renal transplantation. Abstr. of Congr. of the Transplant. Soc., Rome, 2000, aug. 27 - sept. 1.Hardwick L., Savatta S., Book B. et al. Effect of mycophenolate mofetil (MMF) on anti-CMV serologic response after renal transplantation. Abstr. of Congr. of the Transplant. Soc., Rome, 2000, aug. 27 - sept. 1.

The authors declare that there are no conflicts of interest present.